Thyroid carcinoma in children and adolescents presents with several distinct clinical features when compared with adults. First, there is a substantially higher rate of regional and distally metastatic disease. In addition, recurrence rates are higher in this age group (3) . Paradoxically, despite higher initial burden of disease, outcomes in children and adolescents are excellent (4) . Certain histologic variants, including the diffuse sclerosing and solid variants of papillary thyroid carcinoma (PTC) are identified more commonly in children and adolescents (5, 6) . Biologic and molecular mechanisms explaining differing clinical behavior of pediatric and adult PTC have thus far been elusive. A discrete set of conventional somatic variants in BRAF, HRAS, NRAS, and KRAS or gene fusions involving RET or PAX8 are identified in up to 80% of adult thyroid carcinomas (7, 8) . However, several recent studies assessing these variants in children have suggested a lower frequency of variants in these genes than in adults, resulting in a higher proportion of pediatric tumors lacking common oncogenic variants, so called "dark-matter" cases (Supplemental Table 1 ). The oncogenic drivers in this "dark-matter" subset remain unidentified.
Aberrant regulation of microRNA (miRNA) processing has been associated with multiple human malignancies (9) (10) (11) , including differentiated and anaplastic thyroid carcinomas (12) (13) (14) (15) . The DICER1 gene product, DICER1, is an endoribonuclease responsible for processing RNA into small interfering RNA and miRNA, which subsequently posttranscriptionally downregulate messenger RNAs. Pathogenic, typically truncating germline variants in DICER1 cause DICER1 syndrome [Online Mendelian Inheritance in Man (OMIM) 601200], characterized by a spectrum of benign and malignant tumors of mainly pediatric onset. These include pleuropulmonary blastoma, ovarian SertoliLeydig cell tumor, cystic nephroma, pituitary blastoma, and multinodular goiter. Truncating DICER1 mutations are accompanied by characteristic somatic missense mutations affecting highly specific metal ion-binding residues within the RNase IIIb domain in syndromerelated tumors (16) .
In this study, we sought to define the prevalence of DICER1 variants in 40 (30 malignant and 10 benign) consecutive pediatric thyroidectomy specimens (Table 1;  Supplemental Table 2 ). Patients undergoing partial or total thyroidectomy who were ,18 years of age at the time of surgery were identified, and informed consent for participation in this study was obtained. All patients were assessed for a personal or family history of syndromic cancers. Patients were excluded if the indication for thyroidectomy was Graves disease without focal lesion or if consent was declined. Forty consecutive pediatric thyroidectomy specimens were obtained (30 malignant, 10 benign) from patients without a personal or family history of syndromic cancers (Table 1) . Patients 3 and 6 had prior exposure to therapeutic ionizing radiation. No other patients had a history of radiation exposure or iodine deficiency, and no patients received thyroid hormone treatment prior to thyroidectomy.
Materials and Methods

Patients and samples
Patients were followed postoperatively for a median of 22.4 months (range: 0.3 to 94.4 months). Carriers of DICER1-variant tumors were followed for a median of 21 months (6.3 to 94.4 months), whereas those with conventional-variant tumors were followed for 34.4 months (3.6 to 93.3 months) (Supplemental Table 3 ). The duration of follow-up was not statistically different for these two groups (P = 0.27). Patients were considered to have no evidence of disease at follow-up if there was no structural disease identified on ultrasound or radioactive iodine scan, and thyroglobulin was less than 0.5 mg/L with levothyroxine-suppressed thyroid-stimulating hormone. Elevated thyroglobulin without structural correlate was considered biochemically persistent disease, and evidence of persistent malignancy based on imaging was classified as structurally persistent disease. There were no patients who achieved no evidence of disease who subsequently demonstrated disease recurrence. 28.5 (9-60) 29 (7-40) Nodal metastases present, n (%) 10 (59%) 0 (0%)
Abbreviations: NA, not applicable.
Samples were snap-frozen in liquid nitrogen within 30 minutes of excision. DNA was extracted from tissue using the AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Germantown, MD). Constitutional DNA was extracted from peripheral blood mononuclear cells using the Gentra Puregene Blood Kit (QIAGEN) in the Clinical Laboratory Improvement Amendments-College of American Pathologists molecular diagnostic laboratories at The Hospital for Sick Children.
Pathology review
Hematoxylin and eosin-stained pathology specimens were reviewed by two pathologists (O.M. and R.C.) and reported according to a standardized approach. In the case of discrepancy between reviewers, cases were discussed until consensus was achieved. One specimen (case 8) was unavailable for review, and the original pathologists' interpretation was used for the purposes of this study.
Genotyping of conventional PTC-associated alterations
Genotyping for the 17 most common thyroid carcinoma associated genetic alterations in BRAF, HRAS, KRAS, NRAS, RET, and PAX8 (17) was performed by allele-specific quantitative polymerase chain reaction (PCR)/quantitative reverse transcription-PCR using the Thyroid Cancer Mutation Detection Kit and the Thyroid Cancer Fusion Detection Kit (Entrogen Inc., Woodland Hills, CA). Equivocal results were obtained for seven samples that underwent gene fusion analysis. These results were validated using a Digital Droplet PCR assay on a QX200 Digital Droplet PCR System (Bio-Rad, Hercules, CA) utilizing the same oligonucleotides used for the Thyroid Cancer Fusion Detection Kit assay (Entrogen Inc.). Variants screened for are detailed in the Supplemental Methods.
DICER1 sequencing
The full coding region and exon-intron boundaries of DICER1 (NM_177438.2) were sequenced using a customdesigned Fluidigm Access Array (Fluidigm, Markham, Ontario, Canada) (18) . Variants were called using FreeBayes version 0.4.1 via the Galaxy toolshed (www.usegalaxy.org/), and annotation of functional consequences was performed using wANNOVAR (http://wannovar.wglab.org/). Integrative Genomics Viewer (http://software.broadinstitute.org/software/igv) was used to manually visualize variants, which were then validated by Sanger sequencing. Matched-normal DNA was used to determine whether mutations were germline or somatic in origin.
Copy number variation analyses
CytoScanHD Array (Affymetrix, Santa Clara, CA) analysis was performed on 36 tumor samples to screen for genome-wide copy number alterations. DNA was hybridized on a CytoScanHD Array (Affymetrix), and normalization and analysis were performed using the Chromosome Analysis Suite (version 3.2.0.1252; r10346). In addition, CytoScanHD (Affymetrix) was performed in the same manner on peripheral blood mononuclear cell-derived DNA from two patients (patients 2 and 3) whose tumors were found to harbor copy number losses involving the DICER1 locus to determine whether the identified changes were germline or somatic in origin. (Table 2) , consistent with published results (Supplemental Table 1 ). Sequencing of DICER1 identified pathogenic mutations in 3 of 30 (10%) PTCs, all of which lacked conventional alterations, thus accounting for 16.7% (3 of 18) of "dark-matter" cases. Two of 10 (20%) benign lesions were also found to be DICER1 mutated (Table 3 ; Fig. 1 ; Supplemental Table 2 ; Supplemental Figs. 1-4) . The three malignant lesions each harbored two somatically acquired DICER1 alterations, whereas the patients with DICER1-mutated benign nodules each carried a germline truncating mutation and an additional somatic RNase IIIb "hotspot" mutation in the nodule, as has been observed previously (19) (20) (21) (22) . One additional tumor (case 5) carried a synonymous DICER1 variant, and two others (cases 4 and 6) each harbored a polymorphism classified as likely benign according to ClinVar (www.ncbi.nlm.nih.gov/clinvar/; variation IDs: 133971 and 133962, respectively). Neither case showed evidence of a second hit within the DICER1 locus.
Discussion
The prevalence of pathogenic DICER1 variants in this series of pediatric thyroid tumors was determined to be 12.5% (5 of 40) (Supplemental Table 3 ). Two large genome-wide analyses have identified low rates of pathogenic DICER1 variants in adult thyroid tumors. The Cancer Genome Atlas project identified pathogenic somatic DICER1 variants in 2 of 401 (0.5%) PTCs (Supplemental Table 4 ) (7), whereas a subsequent study identified no DICER1-variant tumors among 125 PTC, and two tumors with DICER1 variants in each of 30 minimally invasive follicular thyroid cancers and 25 follicular adenomas (8) . DICER1-mutated PTCs are thus more frequent in the pediatric (3 of 30) than in the adult setting (2 of 526; P = 0.0013, two-sided Fisher exact test). Although capsular or parenchymal invasion was observed among all DICER1-mutated thyroid carcinomas in our series, angioinvasion was only identified in one (case 3). None were associated with local or regional lymph node or distal metastases, and all are thus classified as low risk for persistent/recurrent disease according to the recent American Thyroid Association pediatric management guidelines (3). In contrast, four of five (80%) BRAF V600E tumors and six of seven (86%) RET/PTC tumors were associated with nodal metastases. Antithyroglobulin titers were undetectable in all individuals with DICER1 tumors and were present in 7 of 27 (26%) of the remaining individuals with PTC, a proportion concordant with recent studies (23) . Patients with DICER1-mutated tumors remained disease-free at a median of 21 months follow-up (range: 9.9 to 37.4 months) (Supplemental Table 3 ). None of the DICER1 tumors had a chronic lymphocytic infiltrate, and four cases exhibited focal nonspecific thyroiditis. Lastly, in six of seven DICER1-mutated available specimens reviewed, the background thyroid parenchyma showed variable involutional changes similar to alterations associated with exposure to elevated thyroid hormone concentrations (Table 3 ; Fig. 1 ; Supplemental  Fig. 1 ). DICER1 alterations impact several miRNA species in thyroid lesions (24) . Although multiple studies have demonstrated alterations in miRNA sequence and expression in thyroid malignancies (7, (25) (26) (27) , their mechanistic implications and role in thyroid tumorigenesis remain to be fully elucidated. It also remains to be seen whether alterations in other components of the miRNA processing machinery (DROSHA, DGCR8, AGO2, etc.) are altered in thyroid carcinoma.
Conclusion
DICER1 mutations in pediatric PTC are present at a frequency nearly 30 times that seen in adult PTC. DICER1 malignancies comprised 16.7% of dark-matter tumors in this pediatric series and were not associated with thyroid autoimmunity. These data establish DICER1 as a common oncogenic driver in American Thyroid Association pediatric low-risk PTC and broaden our understanding of the molecular pathogenesis of pediatric PTCs. Further delineation of the role of miRNA processing and aberrations in thyroid carcinogenesis may expand our insight into prognosis and potentially therapeutic approaches.
